New Study Indicates Smallpox Vaccination Effective For Decades

Main Category: Immune System / Vaccines
Also Included In: Infectious Diseases / Bacteria / Viruses;  Bio-terrorism / Terrorism
Article Date: 01 Dec 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population. Under such circumstances, the supply of smallpox vaccine may be insufficient for universal administration. In a study published in the December 2008 issue of The American Journal of Medicine, researchers found that lifetime protection is obtained from just one vaccination, even when that vaccination occurred as much as 88 years ago. They conclude that in the event of a smallpox bioterrorist attack, vaccinia smallpox vaccine should be used first on individuals who have not been vaccinated previously.

Examining 246 participants of the Baltimore Longitudinal Study of Aging, investigators from the National Institute on Aging and the National Institute of Allergy and Infectious Diseases, National Institutes of Health found permanent immunity was conferred by vaccination or by survival from an active smallpox infection. In the sample, 209 subjects were vaccinated one or more times 13 to 88 years prior to the study; an additional 18 had had childhood smallpox, and 29 with no history of vaccination or smallpox were included.

Although the vaccinia virus vaccine was used since the late 18th century, routine vaccination was discontinued more than 30 years ago in many countries. Most Americans under 35 have never been vaccinated and most over 35 have not received booster immunizations since the early 1970s. If a bioterrorist attack were to occur, it would be critical to know who already had effective immunity and would not need to be vaccinated, leaving another dose available for someone else.

Current recommendations relating to smallpox vaccination has been that people with repeated exposure to smallpox, for example travelers to endemic areas, should be revaccinated every five years. This study suggests that such reimmunizations may not be necessary because multiple vaccinations achieve only marginally higher levels of antibody and virus neutralizing activity than single vaccination.

Writing in the article, Dan L. Longo, MD, National Institute on Aging, states "A major question posed today is whether those individuals vaccinated 40 or more years ago would be protected in the event of smallpox exposure. This may be a critical question because the availability of smallpox vaccines is limited and currently inadequate for a mass inoculation program. We found that vaccinated subjects maintain what appear to be protective levels of neutralizing antibodies to vaccinia indefinitely and do not require booster vaccinations even if they are many decades removed from primary vaccination. These data imply that limited supplies of vaccine can be more usefully applied to individuals who have never been vaccinated, primarily individuals born after 1972."

The article is "Immunity from Smallpox Vaccine Persists for Decades: : A Longitudinal Study" by Dennis D. Taub, William B. Ershler, Mark Janowski, Andrew Artz, Michael L. Key, Julie McKelvey, Denis Muller, Bernard Moss, Luigi Ferrucci, Patricia L. Duffey and Dan L. Longo. It appears in The American Journal of Medicine, Volume 121, Issue 12 (December 2008) published by Elsevier.

About The American Journal Of Medicine

The American Journal of Medicine , known as the "Green Journal," is one of the oldest and most prestigious general internal medicine journals published in the United States. It is ranked 11th out of 100 General and Internal Medicine titles according to the 2007 Journal Citation Reports© published by Thomson Reuters.

AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect , MD Consult, Scopus, bibliographic databases, and online reference works.

Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier